Itaconate also ameliorates the severity of bone loss in a mouse model of OVX-induced osteoporosis and restrains ROS production, inflammatory responses and osteoclastogenesis via inhibition of the E3 ubiquitin ligase (Hrd1) to dislocate Nrf2 from ubiquitin (Sun et al., 2019), suggesting it could be a promising candidate for osteoporosis treatment in the future. This evidence concerns the gene SYVN1 and osteoporosis.